Aducanumab Alzheimer antibody, illustration

Numéro d’image : 13443549
Aducanumab Alzheimer antibody, illustration
Illustration showing Aducanumab (purple, lower left), a human-derived monoclonal immunoglobulin G (IgG) antibody binding to amyloid beta plaques (blue and yellow). Amyloid beta plaques are insoluble aggregates of amyloid beta protein. They are believed to be linked to Alzheimer's disease by causing nerve cell death and affecting nerve cell signalling pathways. Aducanumab binds to amyloid beta plaques by targeting an epitope found on the amyloid beta protein. This causes a reduction in beta amyloid plaques in the brain. This could potentially slow down Alzheimer's disease progression, particularly patients in the earlier stages of the disease. On 7th of June 2021, Aducanumab was approved for treatment in Alzheimer's disease by the US Food and Drug Administration (FDA) through its accelerated approval pathway.
Licence : Droits gérés
Crédit: Science Photo Library / Andrade, Ramon / 3dciencia
Taille de l’image : 3653 px × 4870 px
Model Release : Non requis
Property Release : Non requis
Restrictions : -

Prix pour cette image À partir de 45 €

Produit vendu
(Calendrier, Carte postale, Carte de vœux, Impression sur textile, Packaging etc)
À partir de 45 €
Usage commercial
(Affichage, Annonce presse, Annonce TV, Carte, Digital - hors rés. sociaux, Digital - rés. sociaux etc)
À partir de 45 €
Éditorial
(Digital, Journal, Livre, Livre pratique, Magazine, Télévision etc)
À partir de 60 €
Usage non-commercial
(Digital - hors rés. sociaux, Digital - rés. sociaux etc)
À partir de 120 €

Mots clés

;